Skip to main content
Panion & BF Biotech Inc. logo

Panion & BF Biotech Inc. — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,545 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1760

About Panion & BF Biotech Inc.

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
115年第1季財務報告書 — 202601_1760_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled “合併財務報告暨會計師核閱報告” for 民國一一五年及一一四年第一季 and includes a full accountants’ review report plus consolidated balance sheet, income statement, cash flow, statement of changes, and extensive notes. It contains actual financial statements for the quarter rather than merely announcing or linking to a report. This matches the definition of an interim/quarterly report. Q1 2026
2026-05-13 Chinese
公告本公司董事會通過115年第一季合併財務報告
Interim / Quarterly Report Classification · 95% confidence The document is an official announcement on Taiwan’s public information platform (“公開資訊觀測站”) where the listed company announces that its board approved the consolidated financial report for the first quarter (1/1–3/31) of the fiscal year. The text includes substantive financial data: revenue, gross profit, operating profit, pretax and net profit, EPS, assets, liabilities, and equity. This aligns with the definition of an Interim/Quarterly Report (IR). It is not merely a publication notice (RPA) or a brief highlights release (ER), but a full interim report with actual numbers. Q1 2026
2026-05-12 Chinese
114年年報及股東會資料 — 2025_1760_20260525FE4.pdf
Regulatory Filings
2026-05-06 Chinese
114年年報及股東會資料 — 2025_1760_20260525F04.pdf
Regulatory Filings
2026-05-06 Chinese
114年年報及股東會資料 — 2026_1760_20260525F17.pdf
Regulatory Filings
2026-05-06 Chinese
公告本公司115年第一季財務報告董事會預計召開日期 為115年5月12日
Regulatory Filings
2026-05-06 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.